Neogen Co. (NASDAQ:NEOG) – Analysts at William Blair reduced their Q1 2022 EPS estimates for Neogen in a research report issued to clients and investors on Monday, June 7th. William Blair analyst J. Kreger now anticipates that the company will post earnings per share of $0.08 for the quarter, down from their prior forecast of $0.16. William Blair also issued estimates for Neogen’s Q2 2022 earnings at $0.09 EPS.
Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Monday, March 22nd. The company reported $0.06 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.06. Neogen had a return on equity of 8.03% and a net margin of 13.66%. The business had revenue of $116.70 million during the quarter, compared to the consensus estimate of $106.72 million. During the same quarter in the previous year, the firm earned $0.06 earnings per share. Neogen’s revenue for the quarter was up 17.2% compared to the same quarter last year.
NASDAQ NEOG opened at $45.02 on Wednesday. The firm has a market cap of $4.82 billion, a P/E ratio of 38.81 and a beta of 0.49. The firm’s fifty day moving average price is $25.89. Neogen has a twelve month low of $33.11 and a twelve month high of $48.85.
A number of large investors have recently added to or reduced their stakes in NEOG. Signaturefd LLC raised its stake in Neogen by 56.3% during the fourth quarter. Signaturefd LLC now owns 372 shares of the company’s stock valued at $29,000 after buying an additional 134 shares during the last quarter. CWM LLC bought a new stake in shares of Neogen in the first quarter worth approximately $36,000. Endurance Wealth Management Inc. purchased a new stake in Neogen during the 1st quarter valued at $47,000. Sageworth Trust Co purchased a new stake in shares of Neogen during the 1st quarter valued at about $87,000. Finally, Veriti Management LLC purchased a new position in shares of Neogen during the 4th quarter worth $127,000. Institutional investors and hedge funds own 92.26% of the company’s stock.
In other Neogen news, VP Jason Warren Lilly sold 993 shares of the business’s stock in a transaction on Tuesday, April 13th. The shares were sold at an average price of $92.25, for a total value of $91,604.25. Following the completion of the sale, the vice president now directly owns 10,353 shares of the company’s stock, valued at $955,064.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce Papesh sold 7,000 shares of the business’s stock in a transaction dated Thursday, March 25th. The shares were sold at an average price of $85.42, for a total value of $597,940.00. Following the completion of the sale, the director now directly owns 40,261 shares of the company’s stock, valued at approximately $3,439,094.62. The disclosure for this sale can be found here. Insiders have sold 95,380 shares of company stock valued at $8,474,555 in the last quarter. Company insiders own 0.90% of the company’s stock.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Read More: What is the Coverage Ratio?
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.